Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Long-term Immune, Neurobiological, and Gut-vaginal-urinary axis Exhaustion post-UTI: Research and Rehabilitation

Cel

Urinary tract infections (UTIs) affected an estimated 404.6 million people globally in 2019, contributing to nearly 236,786 deaths and 5.2 million Disability-Adjusted Life Years. For a substantial subset of patients (approximately 25–70% of women), a first UTI is not an isolated event but the beginning of a self-reinforcing cycle of recurrence, repeated antibiotic exposure, microbiome disruption, and epithelial vulnerability. The LINGER project (Long-term Immune, Neurobiological, and Gut–vaginal–urinary axis Exhaustion post-UTI: Research and Rehabilitation) aims to provide the first comprehensive molecular characterisation of this post-infection recurrence state and to deliver diagnostic tools, validated interventions, and structured rehabilitation strategies to transform its management.

LINGER is structured around three objectives. (1) Map & Stratify: establish a pan-European cohort of pre-menopausal women (18–50 years) across Germany, the Netherlands, and Italy, and apply integrated multi-omics (targeted genome sequencing, metagenomics, metatranscriptomics, proteomics/peptidomics, epigenomics, and metabolic modelling) and AI-driven analysis to develop the Virtual Urinary-Tract Twin, a predictive model of post-infection recurrence risk. (2) Dissect & Validate: use in vitro (3D urothelial models) and in vivo (mouse rUTI models) systems to identify and validate causal mechanisms. (3) Intervene & Empower: translate findings into a precision Bacterial-Like Particle (BLiP) mucosal immunotherapy, pilot a digital-first patient self-management and education platform (Post-UTI Recovery Programme), and conduct a comprehensive burden-of-illness assessment to support healthcare integration.

By delivering a predictive diagnostic tool, a Phase 1-ready immunotherapy candidate, and an evidence-based digital care platform, LINGER will shift rUTI management from reactive antibiotic use to proactive, precision prevention, advancing innovations from TRL 2–3 to TRL 4–5.

Dziedzina nauki (EuroSciVoc)

Słowa kluczowe

Program(-y)

Temat(-y)

System finansowania

HORIZON-RIA - HORIZON Research and Innovation Actions

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) HORIZON-HLTH-2026-01

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Koordynator

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
Wkład UE netto
€ 1 084 372,50
Koszt całkowity
Brak danych

Uczestnicy (13)